Anterogen.Co.,Ltd. (KOSDAQ:065660)

Market Cap	360.22B +81.3%
Revenue (ttm)	7.54B +8.7%
Net Income	-1.37B
EPS	-138.00
Shares Out	10.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,903
Average Volume	37,483
Open	38,000
Previous Close	37,600
Day's Range	35,750 - 38,000
52-Week Range	19,380 - 61,800
Beta	0.02
RSI	38.40
Earnings Date	n/a

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065660

Financial Performance

In 2025, Anterogen.Co.,Ltd.'s revenue was 7.54 billion, an increase of 8.71% compared to the previous year's 6.93 billion. Losses were -1.37 billion, -40.08% less than in 2024.